Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunotherapy. In addition, in a fraction of nonresponder patients, which can vary from 4 to 29% according to different studies, a paradoxical boost in tumor growth after ICI administration was observed: a completely unpredictable novel pattern of cancer progression defined as hyperprogressive disease. Since this clinical phenomenon has only been recently described, a universally accepted clinical definition is lacking, and major efforts have been made to uncover the biological bases underlying hyperprogressive

SUBMITTER: Camelliti S 

PROVIDER: S-EPMC7650183 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature